Compare Heron Therapeutics Inc (HRTX) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while iShares Broad USD Investment Grade Corporate Bond trades at $50.54. Which is the better fit depends on your goals.
| HRTX | USIG | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Fixed Income |
52-Week High | $1.96 | $52.69 |
52-Week Low | $0.39 | $50.50 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
USIG (iShares Broad USD Investment Grade Corporate Bond ETF) trades at $50.605, down 0.27% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings with RSI at 51.10. Recent corporate actions include dividend payments of $0.20-$0.21 per share. Short interest surged 63.4% in April 2026, indicating growing bearish sentiment among traders.
The ETF faces headwinds from rising short interest and bearish technical positioning. Investment grade corporate bond exposure provides stability but current market sentiment suggests caution. The dividend yield remains modest while technical indicators point to potential near-term pressure on the share price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
